Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cost of Revenue for 9 consecutive years, with $298.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 110.0% year-over-year to $298.3 million; the trailing twelve-month figure through Jun 2026 stood at $970.7 million (up 144.62% YoY), and the FY2025 full-year result was $677.2 million, up 120.93% from the prior year.
• Cost of Revenue rose to $298.3 million in Q2 2026 per ALNY's latest filing, from $207.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $298.3 million in Q2 2026 and bottomed at $23.5 million in Q1 2022.
• Historically, Cost of Revenue has averaged $105.4 million across 5 years, with a median of $73.7 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cost of Revenue dropped 10.71% in 2024, then jumped 195.68% in 2026.
• Over 5 years, Cost of Revenue stood at $46.2 million in 2022, then jumped by 55.88% to $72.0 million in 2023, then surged by 42.62% to $102.6 million in 2024, then soared by 160.81% to $267.7 million in 2025, then climbed by 11.41% to $298.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $298.3 million, $207.5 million, and $267.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.